Researchers found sex-based differences in lung cancer immune responses, with CXCL13 prevalent in females and higher T-cell activation in female tumors.

Researchers at Saint Louis University School of Medicine have found significant sex-based differences in T-cell immune responses in lung cancer patients. Their study revealed that the protein CXCL13, which indicates immunotherapy response, is more prevalent in females. T-cells in female tumors showed high activation levels, while male tumors had more immune-suppressive T-cells. These findings suggest the potential for tailored cancer treatments based on sex.

September 20, 2024
5 Articles